apteka.lviDrugs24.com

Monthly offers  -Prices-Offer price Monthly offers 
Latvian pharmacies maps Duty doctors. medicaid
Medicines and generics searching-PricesDrugs search by alphabet
Vaccination offers. Pricelists-Prices-Offer price Vaccination offers
Space Weather Space weather
    
Queues for medical examinationsLists of compensated medicines        E‑health         
 LV 

JANUMET OBD TBL 50MG/850MG N56

Attention: Information on this site is provided for informational purposes and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for treating a health problem or disease, or prescribing any medication. iDrugs24.com is not responsible for any damage to your health as the result of self treatment.

# On 2024-Mar-29
JANUMET-drug/medicine -tablets aproximate price on "JANUMET OBD TBL 50MG/850MG N56 " in Riga city, Latvia is:
  • 51.97€  56.18$  44.44£  6002Rub  599SEK  224PLN  206.84₪ 


Maximum allowed state defined price ( from ZVA webpage) Euro:State defined maximum allowed price indicated on the picture on drug/medicine -tablets  JANUMET OBD TBL 50MG/850MG N56     Recheck

ATC codeA10BD07 

Active substances: Sitagliptinum Un Metforminum

 


Vendor, principal: Merck Sharp & Dohme
JANUMET OBD TBL 50MG/850MG N56 is compensated medicine in Latvia. 

 Prescription drug (℞) 

Similar or the same name medicines, products list *
Medicament / Item title  Prices Pharmacies chain
JANUMET TBL 850MG/50MG N56
25.82€ , Mar.2024 Pharmacy Estonia Valga südameapteek (Estonia) Phone: +3727668005Buy
JANUMET TBL 1000MG/50MG N56
25.82€, Mar.2024 Pharmacy Estonia Valga selveri apteek. Apotheka.ee (Estonia) Phone: +3727661766 Buy
JANUMET TBL 850MG/50MG N56
25.82€, Mar.2024 Pharmacy Estonia Valga selveri apteek. Apotheka.ee (Estonia) Phone: +3727661766 Buy
JANUMET TBL 1000MG/50MG N56
25.82€, Mar.2024 Pharmacy Estonia Valga südameapteek (Estonia) Phone: +3727668005Buy
JANUMET TBL 850MG/50MG N56
25.82€, Mar.2024 Pharmacy Estonia Benu Apteek (Estonia) Phone: +3726119070Proceed with order
JANUMET ÕHUK. POLÜM.KAT. TBL 1000MG+50MG N56, metformiin, sitagliptiin Rx
25.82€, Mar.2024 Pharmacy Estonia Aptev.ee, OÜ Mai apteek (Estonia) Phone: 6008844Buy
JANUMET ÕHUK. POLÜM.KAT. TBL 850MG+50MG N56, metformiin, sitagliptiin Rx
25.82€, Mar.2024 Pharmacy Estonia Aptev.ee, OÜ Mai apteek (Estonia) Phone: 6008844Buy
JANUMET 50 MG/1000 MG PLĖVELE DENGTOS TABLETĖS N56 Rx
26.46€, Mar.2024 Internet pharmacy Lithuania Gintarinė vaistinė nvaistine.lt (Lithuania) Phone: 880010008Buy
JANUMET 50 MG/850 MG PLĖVELE DENGTOS TABLETĖS N56 Rx
33.02€, Mar.2024 Internet pharmacy Lithuania Gintarinė vaistinė nvaistine.lt (Lithuania) Phone: 880010008Buy
JANUMET 50 MG/850 MG PLĖVELE DENGTOS TABLETĖS N56 (4X14) (Merck Sharp & Dohme B.V.)
33.02€, Jan.2024 Internet pharmacy Lithuania 100 metų vaistinė (Lithuania) Phone: +37038159292Buy
* This table was compiled fully automatically, independently from any advertisers, transparently and without any modification relaying the open offers available on the mentioned dates.Only the distribution of over-the-counter remedies through the website is permitted in Latvia in accordance with national laws and regulations.

EUROPEAN MEDICINES AGENCY

SCIENCE MEDICINES HEALTH

EMA/370017/2013

EMEA/H/C/000861

EPAR summary for the public

Janumet

sitagliptin / metformin hydrochloride

This is a summary of the European public assessment report (EPAR) for Janumet. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Janumet.

What is Janumet?

Janumet is a medicine that contains two active substances, sitagliptin and metformin hydrochloride. It

is available as tablets (50 mg sitagliptin / 850 mg metformin hydrochloride; and 50 mg sitagliptin /

1,000 mg metformin hydrochloride).

What is Janumet used for?

Janumet is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels.

It is used in addition to diet and exercise in the following ways:

•   in patients who are not satisfactorily controlled on metformin (an antidiabetes medicine) used on its own;

•   in patients who are already taking a combination of sitagliptin and metformin as separate tablets;

•   in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin (other types of antidiabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin.

The medicine can only be obtained with a prescription.

An agency of the European Union

WC5EN00038807

7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu

© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

How is Janumet used?

Janumet is taken twice a day. The strength of tablet to use depends on the dose of the other antidiabetes medicines that the patient was taking before. If Janumet is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).

The maximum dose of sitagliptin is 100 mg a day. Janumet should be taken with food to avoid any stomach problems caused by metformin.

How does Janumet work?

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substances in Janumet, sitagliptin and metformin hydrochloride, each have a different mode of action.

Sitagliptin is a dipeptidyl-peptidase-4 (DPP-4) inhibitor. It works by blocking the breakdown of Nincretin' hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By increasing the levels of incretin hormones in the blood, sitagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Sitagliptin does not work when the blood glucose is low. Sitagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. Sitagliptin has been authorised in the European Union (EU) as Januvia and Xelevia since 2007, and as Tesavel since 2008.

Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut. Metformin has been available in the EU since the 1950s.

As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type 2 diabetes.

How has Janumet been studied?

Sitagliptin on its own as Januvia/Xelevia/Tesavel can be used with metformin, and with both metformin and a sulphonylurea, in type 2 diabetes patients. The company presented the results of three studies of Januvia/Xelevia to support the use of Janumet in patients who were not satisfactorily controlled on their existing metformin treatment. Two of the studies looked at sitagliptin as an add-on to metformin: the first compared it with placebo (a dummy treatment) in 701 patients, and the second compared it with glipizide (a sulphonylurea) in 1,172 patients. The third study compared sitagliptin with placebo, when used as an add-on to glimepiride (another sulphonylurea), with or without metformin, in 441 patients.

The results of three further studies were used to support the use of Janumet. The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Janumet with that of metformin or sitagliptin alone. The second included 278 patients who were not satisfactorily controlled on the combination of metformin and rosiglitazone (a PPAR-gamma agonist) and compared the effects of adding sitagliptin or placebo. The third included 641 patients who were not satisfactorily controlled on a stable dose of insulin, three-quarters of whom were also taking metformin. This study also compared the effects of adding sitagliptin or placebo.

In all of the studies, the main measure of effectiveness was the change in the levels of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.

The company carried out additional studies to show that the active substances in Janumet are absorbed by the body in the same way as the two medicines given separately.

What benefit has Janumet shown during the studies?

Janumet was more effective than metformin alone. Adding 100 mg sitagliptin to metformin reduced HbA1c levels by 0.67% (from around 8.0%) after 24 weeks, compared with a fall of 0.02% in the patients adding placebo. The effectiveness of adding sitagliptin to metformin was similar to that of adding glipizide. In the study in which sitagliptin was added to glimepiride and metformin, the levels of HbA1c were reduced by 0.59% after 24 weeks, compared with an increase of 0.30% in the patients adding placebo.

In the first of the three further studies, Janumet was more effective than metformin or sitagliptin alone. In the second, HbA1c levels were reduced by 1.03% after 18 weeks in patients adding sitagliptin to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo. Finally, they were reduced by 0.59% after 24 weeks in patients adding sitagliptin to insulin, compared with a fall of 0.03% in those adding placebo. There was no difference in this effect between the patients also taking metformin and those not taking it.

What is the risk associated with Janumet?

The most common side effect with Janumet (seen in between 1 and 10 patients in 100) is nausea (feeling sick). For the full list of all side effects reported with Janumet, see the package leaflet.

Janumet must not be used in people who are hypersensitive (allergic) to sitagliptin, metformin or any of the other ingredients. It must not be used in patients who have diabetic ketoacidosis or pre-coma (dangerous conditions that can occur in diabetes), problems with the kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack. It must also not be used in patients who consume excessive amounts of alcohol or are alcoholic, or in women who are breast-feeding. For the full list of restrictions, see the package leaflet.

Why has Janumet been approved?

CHMP decided that Janumet's benefits are greater than its risks and recommended that it be given marketing authorisation.

Other information about Janumet

The European Commission granted a marketing authorisation valid throughout the EU for Janumet on 16 July 2008.

The full EPAR for Janumet can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. For more information about treatment with Janumet, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 06-2013.

Janumet

EMA/370017/2013

Page 3/3



 Instruction , annotation source: The European Medicines Agency


[*1]

Information source DDD German Institute of Medical Documentation and Information - DIMDI [23.11.2011]


Back


Facebook Tweeter E-mail link
For pharmacies & healthstores For advertisers About

Copyright © 2011-2024 iDrugs24.com. All rights reserved